P1-17-4EFFICACY OF CARBOPLATIN + WEEKLY NAB-PACLITAXEL FOR ELDERLY ADVANCED/RECURRENT NON-SMALL CELL LUNG CANCER(E-NSCLC)

Abstract Background: French trial showed survival advantage of carboplatin (Cb) + weekly PAC doublet over monotherapy for E-NSCLC patients. Elderly subset of CA310 trial suggested improved overall survival by Cb + weekly nab-paclitaxel (wnPAC) compared with standard Cb + PAC. These trials suggested that Cb + wnPAC could be a reasonable treatment option for E-NSCLC. To examine the efficacy of Cb + wnPAC for E-NSCLC, we conducted a retrospective analysis of the patients who underwent this chemotherapy. Methods: Ten patients aged 75 or older received Cb + wnPAC as the first-line chemotherapy for advanced or recurrent NSCLC. Data of these patients were extracted from electronic medical records. The dose and schedule of the treatment were based on CA310 trial. The treatment was repeated up to 4 courses. Result: Patient characteristics were as follows: Median age 76 (range: 75-78); all male; histology (Sq/Ad/NOS) 6/2/2; PS (0/1/2) 5/2/3; stage (IIIB/IV/recurrent) 2/3/5. Delivered number of courses was 4 in median. Actual/planned dose intensity were 87.5% and 67.3% for Cb and nab-PAC, respectively. Responses by RECIST were PR in 5, SD in 2 and PD in 3. Treatment delay and skip was experienced in 4 and 6 cases, respectively. Dose reduction was needed in 5 cases. Grade 3/4 neutropenia, thrombocytopenia and anemia were experienced in 7, 3 and one patients, respectively. Non-hematological toxicity of G3 was observed in 2 patients (anorexia and fatigue in one, and enterocolitis in the other). No febrile neutropenia or grade 3 neuropathy was observed. Conclusion: Cb + wnPAC can be a good treatment option for E-NSCLC.